miércoles, 25 de octubre de 2023

Pembrolizumab as a first-line treatment for advanced gastric cancer

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00526-0/fulltext?dgcid=hubspot_email_conferencealerts_esmo23&utm_campaign=conferencealerts&utm_medium=email&_hsmi=278988838&_hsenc=p2ANqtz-8_l7lQgOsF3Y-QFY7NhSMG8p4YkEXYDb0s8wXvO8IUsiwu-8CVoKMMxqhvkhFdb28MlpUdLkhZJaF7lGQ3_cEhklfE_w&utm_content=278988838&utm_source=hs_email

No hay comentarios:

Publicar un comentario